Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EMA to revise five-year road map in light of feedback

This article was originally published in Scrip

Executive Summary

The European Medicines Agency is to revise its road map, which sets out its strategic development plans for the next five years to 2015, to take into account the feedback it has received so far. Part of the roadmap's vision is for regulators and industry to start working together earlier in the drug development process in order to improve the chances of approval (for the roadmap's proposals, see, 27 January 2010).




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts